Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decrease in Short Interest
Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decrease in Short Interest
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) saw a significant drop in short interest in August. As of August 15th, there was short interest totalling 2,760,000 shares, a drop of 12.1% from the July 31st total of 3,140,000 shares. Based on an average trading volume of 684,400 shares, the short-interest ratio is presently 4.0 days. Currently, 3.7% of the company's stock are short sold.
赛特克生物科学公司(纳斯达克：CTKB-GET评级)看到空头股数在8月份大幅下降。截至8月15日，空头股数共有276万股，较7月31日的314万股下降了12.1%。以平均成交量68.44万股计算，目前短息比为4.0天。目前，该公司3.7%的股票被卖空。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several equities analysts have recently weighed in on CTKB shares. The Goldman Sachs Group boosted their price target on shares of Cytek Biosciences from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Thursday, August 11th. Morgan Stanley boosted their price objective on Cytek Biosciences from $11.00 to $15.00 and gave the stock an "equal weight" rating in a research note on Friday, August 12th. Finally, Piper Sandler lifted their price target on shares of Cytek Biosciences from $12.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, August 17th.
几位股票分析师最近纷纷买入CTKB的股票。在8月11日星期四的一份研究报告中，高盛夫妇将赛特克生物科学公司的股票目标价从15.00美元上调至17.00美元，并给予该股“买入”评级。摩根士丹利在8月12日星期五的一份研究报告中将赛特克生物科学公司的目标价从11.00美元上调至15.00美元，并给予该股“同等权重”的评级。最后，派珀·桑德勒在8月17日(周三)的一份研究报告中将Cytek Biosciences的股票目标价从12.00美元上调至16.00美元，并给予该公司“增持”评级。
Cytek Biosciences Price Performance
Cytek Bioscions性价比
Shares of NASDAQ CTKB traded up $0.01 during midday trading on Thursday, hitting $11.66. The company's stock had a trading volume of 32,592 shares, compared to its average volume of 856,983. The firm has a market capitalization of $1.57 billion and a price-to-earnings ratio of -582.50. The business's fifty day simple moving average is $12.56 and its two-hundred day simple moving average is $11.47. Cytek Biosciences has a 1 year low of $7.38 and a 1 year high of $28.70.
周四午盘，新浪纳斯达克的股价上涨了0.01美元，达到11.66美元。该公司股票的成交量为32,592股，而其平均成交量为856,983股。该公司市值为15.7亿美元，市盈率为-582.50。该业务的50日简单移动均线切入位为12.56美元，200日简单移动均线切入位为11.47美元。Cytek Biosciences的一年低点为7.38美元，一年高位为28.70美元。
Insider Buying and Selling at Cytek Biosciences
Cytek Biosciences的内部买入和卖出
In other news, CEO Wenbin Jiang sold 20,000 shares of the stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $10.75, for a total transaction of $215,000.00. Following the completion of the sale, the chief executive officer now owns 7,881,541 shares in the company, valued at approximately $84,726,565.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Cytek Biosciences news, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $13.45, for a total value of $47,075.00. Following the completion of the transaction, the chief financial officer now owns 92,563 shares of the company's stock, valued at $1,244,972.35. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Wenbin Jiang sold 20,000 shares of the business's stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $10.75, for a total transaction of $215,000.00. Following the sale, the chief executive officer now directly owns 7,881,541 shares in the company, valued at $84,726,565.75. The disclosure for this sale can be found here. Insiders sold a total of 127,000 shares of company stock worth $1,542,675 over the last three months. Corporate insiders own 15.90% of the company's stock.
在其他消息方面，首席执行官蒋文斌在6月7日星期二的一笔交易中出售了2万股该股。该股以10.75美元的平均价格出售，总成交金额为215,000.00美元。出售完成后，首席执行官现在拥有该公司7,881,541股，价值约84,726,565.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过美国证券交易委员会网站访问该文件。在Cytek Biosciences的其他新闻中，首席财务官Patrik Jeanmonod在8月24日星期三的一次交易中出售了3500股该公司的股票。这些股票的平均价格为13.45美元，总价值为47,075.00美元。交易完成后，首席财务官现在拥有该公司92,563股股票，价值1,244,972.35美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过以下链接获得。此外，首席执行官蒋文斌在6月7日星期二的一次交易中出售了2万股该公司的股票。这些股票以10.75美元的平均价格出售，总成交金额为215,000.00美元。出售后，这位首席执行官现在直接拥有该公司7881,541股，价值84,726,565.75美元。此次拍卖的披露信息可在此处找到。在过去的三个月里，内部人士总共出售了12.7万股公司股票，价值1,542,675美元。公司内部人士持有该公司15.90%的股份。
Hedge Funds Weigh In On Cytek Biosciences
对冲基金参与Cytek Bioscions
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parkwood LLC raised its holdings in Cytek Biosciences by 44.3% in the second quarter. Parkwood LLC now owns 42,292 shares of the company's stock valued at $42,000 after acquiring an additional 12,981 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Cytek Biosciences by 64.1% in the 1st quarter. Royal Bank of Canada now owns 5,995 shares of the company's stock valued at $65,000 after purchasing an additional 2,341 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its position in shares of Cytek Biosciences by 31.5% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock worth $69,000 after purchasing an additional 1,536 shares during the last quarter. Lazard Asset Management LLC acquired a new position in shares of Cytek Biosciences during the second quarter worth $70,000. Finally, Ameritas Investment Partners Inc. increased its holdings in Cytek Biosciences by 514.7% in the first quarter. Ameritas Investment Partners Inc. now owns 7,567 shares of the company's stock valued at $82,000 after buying an additional 6,336 shares during the last quarter. Hedge funds and other institutional investors own 43.54% of the company's stock.
对冲基金和其他机构投资者最近改变了他们在该股的头寸。Parkwood LLC在第二季度将其在Cytek Biosciences的持股增加了44.3%。Parkwood LLC现在拥有42,292股该公司股票，价值42,000美元，上个季度又收购了12,981股。加拿大皇家银行在一季度增持赛维生物科技股份64.1%。加拿大皇家银行在上个季度又购买了2341股，现在持有5995股该公司股票，价值6.5万美元。纽约大都会人寿保险公司在第一季度将其在Cytek Biosciences股票的头寸提高了31.5%。纽约大都会人寿保险公司目前持有该公司6,415股股票，价值6.9万美元，此前该公司在上个季度又购买了1,536股。Lazard Asset Management LLC在第二季度收购了Cytek Biosciences价值7万美元的新股票头寸。最后，ameritas Investment Partners Inc.在第一季度增持了Cytek Biosciences 514.7%的股份。Ameritas Investment Partners Inc.现在持有该公司7,567股股票，价值82,000美元，上一季度又购买了6,336股。对冲基金和其他机构投资者持有该公司43.54%的股份。
Cytek Biosciences Company Profile
赛特克生物科学公司简介
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- How will the chip ban affect Nvidia's stock?
- Is Best Buy A Sneaky Buy for Q4?
- Does The Bed Bath and Beyond Stock Rally Still Have Legs?
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 芯片禁令将如何影响NVIDIA的股票？
- 百思买是第四季度的Sneaky Buy吗？
- Bed Bath和Beyond Stock Rally还有腿吗？
- 阿里巴巴-SW和百度集团-SW最终能在退市恐惧中重整旗鼓吗？
- 世界摔跤娱乐公司准备被出售了吗？
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。